Floatz logo

POLY((N-(2-HYDROXYPROPYL)METHACRYLAMIDE)-CO-(METHACRYLOYL-GLY-PHE-LEU-GLY AMIDE WITH O-((TRANS-4-AMINOCYCLOHEXYL)CARBAMOYL)FUMAGILLOL)) (~0.91:0.09 X)

Breast Cancer

Memorial Sloan Kettering Cancer CenterOtherPhase 2Active
CCC
50/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
59/ 100

Competitive context

890 Active assets in the Breast Cancer cohort.

Asset / SponsorPhaseRating
Lapatinib
University of New Mexico
Phase 3BBB
Darolutamide
Vandana Abramson
Phase 2BBB
Trastuzumab Duocarmazine
Byondis B.V.
Phase 3BB
ERIBULIN MONOMETHANESULFONATE
Henan Cancer Hospital
Phase 4BB
Palbociclib
Hoffmann-La Roche
Phase 4BB

View all 50 →

Same molecule, other indications

POLY((N-(2-HYDROXYPROPYL)METHACRYLAMIDE)-CO-(METHACRYLOYL-GLY-PHE-LEU-GLY AMIDE WITH O-((TRANS-4-AMINOCYCLOHEXYL)CARBAMOYL)FUMAGILLOL)) (~0.91:0.09 X) is also rated in:

triple-negative breast carcinomaDormant
CCC
Indicative ·
53 / 100
View asset →
HR+/HER2-negative Breast CancerDormant
CCC
Indicative ·
48 / 100
View asset →
cancerDormant
CC
Indicative ·
46 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →